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CONNECTIVE TISSUE ACTIVATION 
XXXV Detection of Connective Tissue Activating Peptide-I11 Isoforms in 
Synovium from Osteoarthritis and Rheumatoid Arthritis Patients: 
Patterns of Interaction with Other Synovial Cytokines in Cell Culture 
C. W. CASTOR, E. M. SMITH, P. A. HOSSLER, M. C. BIGNALL, and B. P. AARON 
Objective. To determine whether extracts of un- 
incubated osteoarthritis (OA) and rheumatoid arthritis 
(RA) synovial tissue contain connective tissue activating 
peptide-I11 (CTAP-111) isoforms and prostaglandin E, 
(PGE,), and whether such extracts have growth- 
promoting activity, and to determine whether binary 
combinations of CTAP-I11 with other cytokines reported 
to be present in synovial tissue lead to synergistic, 
additive, or inhibitory effects on growth. 
Methods. Acid-ethanol extracts of human syn- 
ovium were examined for growth-promoting activity by 
measuring formation of ''~-g~ycosaminog~ycan (I4c- 
GAG) and 'H-DNA in synovial cell cultures; PGE, was 
measured by enzyme immunoassay, and CTAP-I11 iso- 
forms were identified by Western blotting of extracted 
proteins separated by sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis. Growth-promoting activity of 
CTAP-I11 and other cytokines was tested in synovial 
cultures treated with the agonists singly and in binary 
combination, by measuring changes in synthesis of 
I4C-GAG and 'H-DNA. 
Results. Platelet-derived CTAP-I11 and a cleav- 
age isoform with the electrophoretic mobility of CTAP- 
III-des 1-15heutrophiLactivating peptid1+2 (NAP-2) 
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and PGE, were found in biologically active extracts of 
synovial samples from patients with RA and OA. Five 
growth factors (recombinant epidermal growth factor 
[rEGF], recombinant interleukin-lp [rIL-lP], basic fi- 
broblast growth factor [bFGF], PGE1, and PGE,) in 
binary combination with CTAP-I11 showed synergism in 
stimulating GAG synthesis; two (recombinant platelet- 
derived growth factor type BB [rPDGF-BB] and recom- 
binant transforming growth factor p [rTGFp]) had an 
additive effect. In combination with CTAP-111, rEGF 
and rPD"JF-BB had a synergistic effect in promoting 
DNA synthesis, rTGFP and rbFGF had an additive 
effect, and rIL-lP, PGE,, and PGE, were antagonistic. 
Conclusions. The results suggest that, in addition 
to endogenous factors, CTAP-I11 and other platelet- 
derived cytokines may play roles in regulatinb synovial 
cell metabolism in RA and OA, and that combinations of 
growth factors may be more significant than single 
agents in amplification or suppression of important cell 
functions. 
Cytokines that may participate in driving the 
proliferative and destructive activity of rheumatoid 
synovitis are derived from (a) synovial fibroblastic 
(type B) or macrophage-like (type A) cells, endothelid 
cells, and lymphoid cells resident in the hyperplastic 
synovial membrane itself, and/or (b) components from 
the circulation that are targeted to the joints (1-5). 
Earlier experiments indicated that extracts of both 
normal and rheumatoid human synovial cells grown in 
cell culture had substantial growth factor activity 
when tested against normal synovial cell cultures; 
rheumatoid synovial cells had -4 times the growth- 
promoting activity found in normal cells (1,2). In the 
last 2 decades many components of synovial tissue 
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with biologic activity have been resolved into a variety 
of well-defined growth factors; many are thought to be 
synthesized by cell types found in intact synovial 
tissue (6-8). Growth factors of endogenous origin 
reported in rheumatoid arthritis (RA) synoviurn in- 
clude interleukin-I (IL-l), IL-6, tumor necrosis factor 
a (TNFa),  macrophage colony-stimulating factor, 
granulocyte-macrophage colony-stimulating factor, 
interferon- y, basic fibroblast growth factor (bFGF), 
platelet-derived growth factor (PDGF), connective tis- 
sue activating peptide-V (CTAP-V), and possibly, 
transforming growth factor P (TGFP). 
Since earlier evidence showed that both leuko- 
cyte and platelet extracts have potent cytokine activ- 
ities when added to synovial cell cultures, it is impor- 
tant to consider their potential effect in the diseased 
synovium (3,4). In active RA, large numbers of poly- 
morphonuclear cells are continuously targeted to 
joints: most apparently exit the synovial membrane 
and ultimately make their way into the synovial fluid. 
If platelets are similarly targeted to inflamed joints, 
significant quantities of platelet-derived cytokines may 
be delivered to  the inflamed human synovial mem- 
brane. Well-described platelet-derived cytokines in- 
clude PDGF (9), CTAP-111 (l0,l l) .  TGFP (12), an 
epidermal growth factor (EGF)-like protein (13), and a 
platelet-derived endothelial cell growth factor (14). 
Evidence suggesting a link between platelets 
and articular inflammation includes the association 
between thrombocytosis and decreased platelet sur- 
vival time in patients with severe RA (15-21). Direct 
evidence indicating significant platelet traffic through 
inflamed synovial membrane includes detection of 
extravascular platelets and/or platelet antigens in RA 
and other inflammatory synovial membranes and joint 
fluid samples (22-26). An important observation was 
the demonstration that ' "indium-labeled platelets can 
localize to  inflamed rheumatoid joints (15). 
In the present study, we have shown that 
extracts of unincubated RA and osteoarthritis (OA) 
human synovial tissue contain growth-promoting ac- 
tivities. Agents in these extracts that may contribute to  
these activities were shown to include prostaglandin 
E, (PGE,), CTAP-111, and a cleavage isoform(s) with 
the electrophoretic mobility of CTAP-III-des 1-15/ 
neutrophil-activating peptide-2 (NAP-2). Further, uti- 
lizing many of the cytokines thought to be present in 
inflammatory synovium, we measured the effects of 
several binary combinations of factors on growth- 
related activities in synovial cell cultures. 
MATERIALS AND METHODS 
Extraction of human synovial tissue. Synovial tissue 
removed during arthrotomy or joint replacement surgery 
was fixed for morphologic studies, and the remainder was 
stored at -80°C for extraction studies. Aliquots of each 
sample were weighed and dried to a constant weight over a 
desiccant at 37°C for several days; water content was 
determined by the difference. Weighed aliquots (0.9-1.1 gm) 
of frozen tissue were also homogenized with a Virtis 45 
Micro Homogenizer (The Virtis Co., Gardiner, NY) for - 10 
minutes at 4°C in 2 ml or 3 ml of an extraction vehicle. 
Extraction vehicles were either phosphate buffered saline 
(PBS), pH 7.0, or acid-ethanol (95% ethanol-5% 1.25N 
HCI). After homogenization, extraction was continued for 48 
hours at 4°C with slow stirring. Extracts were centrifuged at 
20,000~ for 10 minutes, and the supernatant fluid was dia- 
lyzed against Dulbecco's phosphate-buffered saline (D-PBS) 
and filter sterilized prior to testing for biologic activity. 
Samples of supernatant fluid to be examined by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE) were dialyzed against water, lyophilized, and recon- 
stituted in a smaller volume for study. 
Tissue prostaglandin measurements. OA and RA syn- 
ovial tissue was homogenized in acid-ethanol as noted above 
and analyzed for PGE, content (27). In a solid-phase extrac- 
tion, samples were adsorbed onto prewetted C-18 cartridges, 
the cartridges washed with 20% methanol, and the eico- 
sanoids eluted with 80% methanol. Eluates were dried under 
an airstream and reconstituted with assay buffer. Extraction 
recoveries, typically 70-80%, were monitored with a radio- 
active thromboxane tracer, and assay results corrected 
accordingly. An ACE enzyme immunoassay (EIA) kit (Cay- 
man, Ann Arbor, MI) was used, with acetylcholinesterase- 
linked PGE, as tracer, rabbit anti-PGE, as the first antibody, 
and a mouse anti-rabbit monoclonal as the second antibody. 
The range of detection for the assay is 2.6-250 pglml. 
Isolation of CTAP-111. CTAP-I11 was isolated from 
human platelets by acid-ethanol extraction, acetone precip- 
itation, gel filtration, heparin affinity chromatography, and 
immunoaffinity chromatography as reported previously 
(1 1,28). CTAP-111 in human synovial tissue was extracted 
with acid-ethanol and dialyzed against PBS for subsequent 
testing. 
Protein measurement and development of antiserum. 
Protein was measured by a colorimetric method (29) and/or 
by ultraviolet absorption (30). Antiserum to platelet-derived 
CTAP-I11 and recombinant CTAP-I11 (&TAP-111) was 
raised in rabbits. Male New Zealand white rabbits 8-10 
weeks old were immunized with 500 pg of CTAP-111 in 
0.15M NaCl in Freund's complete adjuvant. Booster injec- 
tions with antigens in incomplete Freund's adjuvant were 
given 6 weeks and 12 weeks later. Animals were bled at 4 
weeks and then at biweekly intervals after the initial immu- 
nization. Measurement of CTAP-111 by radial immunodiffu- 
sion utilized filtered, heat-inactivated rabbit anti-human 
Analytic polyacrylamide gel electrophoresis. CTAP- 
111 and its isoforms were analyzed by SDS-PAGE in 8M 
urea-8% total acrylamide (28,31). Proteins separated by 
SDS-PAGE were detected by both silver and Coomassie 
CTAP-111. 
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brilliant blue R-250 staining (28,32). Proteins were separated 
by SDS-PAGE and prepared for Western blotting by trans- 
ferring onto Immobilon-P using a semi-dry blotter (Polyblot; 
American Bionetics, Hayward, CA) and then identified by 
Coomassie brilliant blue R-250 and immunostaining with 
antisera to rCTAP-111 (28,3 I ) .  Alternatively, Western blots 
of proteins following electrophoretic separation were per- 
formed by immobilization in a nitrocellulose membrane (28). 
Membrane-bound antigens were probed with antisera to 
rCTAP-111 (1:500 or 1:2,OOO), and the complexes were 
detected with an Immunoblot assay kit (Bio-Rad, Richmond, 
CA) by staining for horseradish peroxidase or for alkaline 
phosphatase using the amplification method. 
Amino acid sequence determination. Aqueous protein 
solutions were applied to a glass-fiber filter pretreated with 
2.0 mg of Biobrene (Applied Biosystems, Foster City, CA) 
and subjected to NH,-terminal sequencing using an Applied 
Biosystems 470A Gas Phase Protein Sequencer interfaced 
with an Applied Biosystems 120A Analyzer (33). 
Cell culture methods. Cultures of normal human and 
rheumatoid synovial cells were developed from explants 
obtained at arthrotomy (34,35). Monolayer cultures were 
grown in T-75 flasks in CMRL 1066 medium (Gibco, Grand 
Island, NY) supplemented with 5% human serum, 10% 
neonatal calf serum, 5% fetal calf serum (FCS), sodium 
bicarbonate, L-glutamine, 0.02M HEPES buffer, penicillin, 
streptomycin, and gentamicin. Cell strains were studied at 
passages 2-5 after removal from explants with trypsin. 
Measurement of growth by isotope incorporation stud- 
ies. Measurement of 14C-glucosamine incorporation into 
14C-glycosaminoglycan ( I4C-GAG), primarily ''C-hyaluron- 
ic acid (I4C-HA), was accomplished by plating cells in 
96-well microtiter plates at  a density of lo4 cells/well in 2004 
of semisynthetic medium (Leibovitz medium, L-15; Hazel- 
ton Biologics, Lenexa, KS) containing I% FCS, L-glu- 
tamine, penicillin, gentamicin, streptomycin, sodium car- 
bonate, and 0.02M HEPES buffer, pH 7.6 (28,36). Test 
materials and control vehicles were in contact with the cells 
for -44 hours before medium was harvested for assay. 
Incorporation of isotope into secreted I4C-HA was measured 
by scintillation counting, following the cetylpyridinium chlo- 
ridefixation wash procedure (28,36). 
To measure 'H-thymidine incorporation into syn- 
ovial cell DNA, cells were plated at lo4 cells/microtiter well, 
in 100 pl of Eagle's synthetic medium (ESM) supplemented 
with 1% FCS, antibiotics, L-glutamine, and HEPES buffer 
and incubated in a humidified chamber at 35-37°C (28,371. 
After a preliminary 20-hour incubation, test samples or 
vehicles were added (5-15 pl/well) and incubation continued 
for 24 hours; 'H-methylthymidine (1.5 pCiIl5 ~1 ESM/well) 
was then added, and incubation was resumed for 24 hours. 
Medium was aspirated, discarded, and cell sheets were 
washed twice, each separately, with PBS, pH 7.0, 5% 
trichloroacetic acid, and absolute methanol. After air drying 
at 35"C, the cells were lysed for 1 hour at 37°C with 50 pl of 
0.3N sodium hydroxide. Fifty microliters of cell lysate was 
pipetted into a counting vial containing Ecolume cocktail, 
and radioactivity was measured in a scintillation counter. 
Cytokine interaction studies. Native CTAP-111 was 
prepared in our laboratory. Recombinant cytokines were 
obtained from the following sources: PDGF from PDGF Inc. 
(Boston, MA), rTGFP from Biosource International (West- 
lake Village, CA), bFGF from Synergen, (Boulder, CO), 
rIL-lP from Intergen (Purchase, NY), rEGF from Collabo- 
rative Research, (Bedford, MA), PGE, from Upjohn Phar- 
maceutical (Kalamazoo, MI), and PGE, from Warner Lam- 
bert Research Institute (Morris Plains, NJ). 
The interactive effects of cytokines in combinations 
of two were tested in bioassays employing nonrheumatoid 
human synovial cells. Dose-response curves were set up to 
measure the magnitude of single growth factor effects on 
I4C-GAG synthesis and 'H-DNA formation and to define 
saturation levels for these experimental conditions. The 
interaction of two cytokines (A and B) was then tested by 
adding an intermediate amount of a second agent (B) at the 
low and high ends of the dose-response curve for the first 
agent (A). Growth factors were added to well cultures at 
room temperature, the second agent following the first 
within a minute. Within the framework of the same experi- 
ment, the reverse study was also done: that is, a dose- 
response curve of cytokine B was supplemented at its high 
and low ends by cytokine A and the metabolic consequences 
were measured. In the graphic presentation of the cytokine 
data, each data point is the mean of values obtained from at 
least 4 microtiter wells. Standard error bars are incorporated 
into all figures; in many figures the error bar is so small, it is 
hidden within the data point symbol. 
RESULTS 
Composition and biologic activity of synovial 
tissue extracts. Approximately 85% of the wet weight 
of human synovium is water (83.5 2 3.9%, mean 2 1 
Table 1. Characteristics of synovial tissue extracts* 
Synovial Protein Biologic activity, 
tissue Degree of Extrac- concentra- incremental cpmt 
sample no. inflamma- tion pro- tion, pg/ 
(diagnosis) tion cedure mlt I4C-GAG 3H-DNA 
4 PBS 568.0 2,128 96 I 
2 PBS 415.0 2,173 2,236 
4 Acid- 59.8 711 27,229 
2 Acid- 40.0 689 14.504 




* Tissue was obtained from 2 patients with rheumatoid arthritis 
(RA) and 1 with osteoarthritis (OA). The degree of inflammation was 
estimated from stained sections: 0 = no hyperplasia or cellular 
infiltration, and 4 = marked synovial hyperplasia, cellular infiltra- 
tion, and capillary growth. GAG = glycosaminoglycan; PBS = 
phosphate buffered saline. 
t Concentrations shown reflect the amount used in culture wells to 
assess growth-related activity. 
t Incremental cpm = total cpm per I 0 0  pl medium (GAG) or total 
cpm per 104 cells (DNA) in experimental wells minus control values 
from vehicle-treated wells. 
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SD of 5 samples). Seven to fifteen percent of the dry 
residue was saline extractable, and I-2% was exlract- 
able with acid-ethanol. Both the relatively protein-rich 
saline extracts and the acid-ethanol extracts stimu- 
lated DNA and GAG synthesis by synovial cells in 
culture; clearly, the specific activity in relation to total 
protein is greater for the acid-ethanol extracts (Table 
I )  (calculations not shown). SDS-PAGE of the ex- 
tracts showed that most of the extracted proteins were 
large. with mobilities similar to that of albumin. Radial 
immunodiffusion measurements identified albumin as 
76% of the protein extracted from RA tissue with 
acid-ethanol, while 30% of the protein extracted by 
this procedure from OA tissue was albumin. I'GE, 
extracted by acid-ethanol was measured by EIA, and 
the results are presented in Table 2. There was marked 
variability among samples: Both low concentrations 
and relatively high concentrations of PGE, were seen 
in samples from both inflammatory disease synovium 
and degenerative joint disease synovium. 
Detection of CTAP-111 isoforms in extracts of 
human synovium. Acid-ethanol extracts of OA and RA 
synovium were shown, by SDS-PAGE and Western 
blot utilizing anti-rCTAP-Ill antisera, to  contain 
CTAP-I11 and its small isoforms (Figure 1). The sam- 
ples from RA patients each showed a band with the 
mobility of CTAP-111 and a second, smaller band with 
the mobility of CTAP-III-des 1-WNAP-2. A sample 
from a patient with juvenile rheumatoid arthritis 
showed 1 band at 9.0 kd and 1 at 6.2 kd (results not 
shown). Only the 6.2-kd form of CTAP-Ill was recov- 
ered from the extract of normal-appearing synovium 
from 1 patient with OA. Lanes 2 and 5 in Figure 1 also 
reveal higher molecular weight isoforms (15-16 kd) 
which are recognized by the anti-rCTAP-111 antibody; 
Table 2. 
tissue* 
Prostaglandin E2 (PGE,) in extracts of human synovial 
PGEz 
Sample no. Degree of ng/ml tissue 
(diagnosis) inflammationt ng/gm tissue wa?er 
1998 (RA) 4 2.7 3.2 
1999 (OA) 1 0.8 1 .o 
2008 (JRA) 4 70.9 85.0 
2009 (OA) 2 25.3 30.3 
2010 (RA) 4 0.25 0.29 
~ ~ ~ ~~ 
* PGEz samples were obtained in acid-ethanol extracts. KA = 
rheumatoid arthritis; OA = osteoarthritis; JRA = juvenile rheuma- 
toid arthritis. 
t See Table 1. 
Figure 1. Western blot of synovial cell extracts from patients with 
rheumatoid arthritis (RA) or osteoarthritis (OA), stained with alka- 
line phosphatase to demonstrate connective tissue activating pep- 
tide-Ill (CTAP-111) and its cleavage isoforms. Lane 2. Sample 1997; 
lane 3. sample 1998; lane 4, sample 1999; lane 5 .  sample 2009 (see 
Tables I and 2). Higher molecular weight isoforms were also 
detected with patient samples. Lane 1 shows the mobility of 
CTAP-111 purified from blood bank platelet packs outdated for 
clinical use (-6 days post-blood donation). After imunoaffinity 
purification, the preparation was shown by amino-terminal sequenc- 
ing to be the CTAP-111 parental form. In spite of prolonged exposure 
to plasma components, 6.2-kd proteolytic cleavage forms are not 
seen. 
these probably represent disulfide-linked dimers and 
are of unknown biologic significance. 
It is important to judge whether the processed 
forms of CTAP-I11 are derived from the extravascular 
domain of the synovial membrane or whether they 
might be easily found within the plasma compartment. 
lndirect evidence bearing on this issue derives from 
examination of the CTAP-I11 isoforms discharged by 
platelets into the platelet-rich plasma of platelet packs 
from a blood bank (lane 1, Figure 1). It is clear that 
CTAP-Ill in the plasma environment remains mostly 
in the 9.3-kd form for several days, in contrast to the 
CTAP-I11 isoforms in synovial extracts, which exhibit 
a marked degree of processing to  a smaller form(s). 
Growth effects of synovial cytokines. In prelimi- 
nary studies (results not shown), recombinant PDGF 
type AA (rPDGF-AA) and EGF were weak stimula- 
tors of synovial cell growth, measured as increases in 
I4C-GAG and 'H-DNA. In contrast, CTAP-111, rP- 
DGF-BB, and rTGFP markedly stimulated these 
growth parameters. Recombinant IL-Ip behaved dif- 
ferently in that it was a potent stimulant of I4C-GAG 
formation but inhibited 'H-DNA synthesis, under con- 
ditions where PGE, synthesis was not blocked. It was 
of interest that, at saturating concentrations of the 
individual agents, the most potent agonists induced 
similar levels of growth stimulation. CTAP-I11 is found 
in serum at concentrations of 1040 pg/ml; it was 
active at concentrations well below this range in these 
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Figure 2. Growth effects of connective tissue activating peptide-I11 (CTAP-111) in combination with recombinant 
platelet-derived growth factor type BB (rPDGF-BB) in synovial cell cultures. The combination of CTAP-111 and 
rPDGF-BB had a synergistic effect on promotion of DNA synthesis; the effect on stimulation of glycosaminoglycan (GAG) 
formation was additive. Values are the mean and SEM. 
assays. The other agents were active in the low ng/ml 
and high pg/ml range. Little data are available con- 
cerning plasma or tissue levels of these agonists. 
Interactions of synovial cytokines in binary com- 
binations. Although the actual number of cytokines 
that play a significant functional role in the synovial 
membrane is unknown, there is evidence for the 
presence of 10-12 separate agonists, including the 6 
studied in the present investigation. It is not unreason- 
able to expect that resident synovial cells are con- 
fronted with many or most of the possible cytokines in 
variable combinations. The number of combinations of 
n different growth factors, taken r at a time, may be 
expressed as: 
C(n,r) = n!/r! (n - r)! 
Thus, the number of combinations of 10 growth fac- 
tors, taken 2 at a time, is 45; if taken 3 at a time there 
are 120 combinations, taken 4 at a time the number 
would be 210, etc. These combinations of cytokines 
might have effects that are antagonistic, additive, or 
synergistic; it is also possible that the metabolic effects 
of combinations are not very different from those of 
single agents. Several combinations of two agonists 
were examined in the present investigation. 
Measurements of the growth effects of CTAP- 
111 in combination with other agonists are shown in 
Figures 2-7. CTAP-111 and rPDGF-BB were mutually 
synergistic in stimulating 3H-DNA synthesis in syn- 
ovial cell cultures (Figure 2). The combination of 
CTAP-111 and rPDGF-BB increased DNA synthesis to 
levels 2-3 times the sum of their individual values. 
Both agents stimulated I4C-GAG synthesis to a similar 
degree; in combination, the effects appeared to be fully 
additive. Recombinant EGF alone had less growth- 
stimulating activity in the GAG and DNA assays than 
did CTAP-111 (Figure 3). Treatment with a combina- 
tion of rEGF and CTAP-111 caused a moderately 
synergistic interaction in stimulating I4C-GAG synthe- 
sis; while the increase was severalfold higher than the 
maximum value with rEGF alone, it represented only 
a 33% increase over the maximum with CTAP-111 
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Figure 3. Growth effects of CTAP-I11 in combination with recombinant epidermal growth factor (rEGF) in synovial cell 
cultures. The combination of CTAP-111 and rEGF had a clearly synergistic effect on promotion of both GAG and DNA 
synthesis. Values are the mean and SEM. See Figure 2 for other definitions. 
alone. These 2 agonists in combination also stimulated 
DNA formation in a synergistic manner; the maximum 
level of DNA synthesis was more than doubled by 
addition of a low concentration of rEGF, which had 
little activity alone. 
Recombinant bFGF at saturating concentra- 
4 x loo00 
0 $ - Y  
O L  - - ' - ' - - ' - ' 
0 5 10 15 20 25 30 
CrAP-m. rolml 
(TAP-m. pghnl 
tions was less potent than CTAP-111 in stimulating 
DNA synthesis; however, the agonists had similar 
activity in promoting GAG formation (Figure 4). Syn- 
ovial cell cultures exposed to CTAP-I11 and bFGF in 
combination showed a simple additive effect in the 
DNA assay and a modest synergistic effect with re- 
0.0 1 .o 2.0 
MGF, ng/ml 
Figure 4. Growth effects of CTAP-111 in combination with recombinant basic fibroblast growth factor (rbFGF) in synovial 
cell cultures. The combination of CTAP-111 and r b € G F  had an additive effect on promotion of DNA synthesis and a 
synergistic effect on stimulation of GAG formation. Values are the mean and SEM. See Figure 2 for other definitions. 
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Figure 5. Growth effects of CTAP-I11 in combination with recombinant transforming growth factor /3 
(rTGF-p) in synovial cell cultures. The combination of CTAP-111 and rTGF-B had a partly additive effect on 
stimulation of GAG formation and a weakly additive effect on promotion of DNA synthesis. Values are the 
mean and SEM. See Figure 2 for other definitions. 
spec1 to GAG synthesis. Recombinant TGFP and 
CTAP-I11 at maximum stimulatory concentrations in- 
duced similar increments in DNA synthesis; rTGFp, 
however, was less effective in stimulating GAG syn- 
thesis (Figure 5) .  The combination of rTGFp and 
CTAP-111 was incompletely additive in promoting 
GAG and DNA formation; in the case of DNA, the 
additive effect was often detectable only with very low 
concentrations of the agonists. Recombinant IL-1p 
caused a decrease in DNA synthesis, and when com- 
bined with CTAP-111, it had an antagonistic effect on 
the mitogenic action of the platelet-derived agent 
(Figure 6). Recombinant IL-1p was a potent inducer of 
synovial 14C-GAG synthesis, and in combination with 
CTAP-111, it had a moderately synergistic effect on 
promotion of GAG formation. 
Interactions of PGE, and PGE, with CTAP-111 in 
synovial cell culture. PGE, and PGE, showed a similar, 
modest ability to stimulate GAG synthesis and depress 
DNA formation in basal synovial cell cultures (Figure 
7). Each prostaglandin had a markedly synergistic 
effect with CTAP-111 in promoting GAG formation, 
and each partially reversed CTAP-I11 stimulation of 
DNA synthesis. In these experiments, PGE, had a 
greater specific activity than did PGE,, especially with 
respect to reducing CTAP-111-stimulated DNA syn- 
thesis. Of interest, CTAP-I11 stimulation of DNA 
synthesis was not completely suppressed by PGE, and 
PGE, even at higher concentrations. 
DISCUSSION 
We have demonstrated growth factor activity in 
extracts of unincubated synovial membranes from 
patients with osteoarthritis and rheumatoid arthritis: 
DNA synthesis was stimulated by as much as 240% 
and GAG formation by up to 680% in human synovial 
cultures exposed to such extracts. Prostaglandins, 
measured as PGE,, were found in concentrations 
ranging from 0.3 to 85.0 ng/ml tissue water, determi- 
nations that should be regarded as minimal values. 
Tissue PGE, concentrations had no obvious relation to 
degree of inflammation, as judged by light microscopy 
of tissue sections. It was, however, of interest that the 
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Figure 6. Growth effects of CTAP-Ill in combination with recombinant interleukin-l/3 (rIL-lp) in synovial 
cell cultures. Recombinant IL-lp had an antagonistic effect on CTAP-Ill promotion of DNA synthesis: the 
combination of CTAP-111 and rlL-1/3 had a synergistic effect on stimulation of GAG formation. Values are the 
mean and SEM. See Figure 2 for other definitions. 
concentrations detected were clearly in a range that 
modifies growth activity in vitro, by acting either alone 
or in combination with defined protein growth factors. 
Detection of CTAP-111 in acid-ethanol extracts 
of human synovial tissue was accomplished by Wzst- 
ern blotting using monospecific polyvalent rabbit anti- 
serum raised against recombinant CTAP-111. This an- 
tiserum is specific in its recognition of native CTAP-111 
and its des 1-13, 1-14, and 1-1YNAP-2 cleavage iso- 
forms. In spite of the marked homology CTAP-111 
shares with platelet factor 4, NAP-1/IL-8, and mela- 
noma growth stimulation activator (MGSA), anti- 
rCTAP-111 antiserum does not recognize these pro- 
teins. The finding that CTAP-111 was present in 
10 1s 20 25 0 S 
Figure 7. Growth effects of CTAP-Ill in combination with prostaglandin E,  (PGE,) and PGE, in synovial cell cultures. The 
combination of CTAP-I11 with either PGE, or PGEz had a synergistic effect on stimulation of GAG formation; both PGE, 
and PGE, partially antagonized the mitogenic effect of ihe platelet agent. Values are the mean and SEM. See Figure 2 for 
other definitions. 
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synovial extracts was of interest for several reasons. It 
was detected as easily in OA tissue as in RA tissue; in 
both cases, a major component was in a low molecular 
weight isoform with the electrophoretic mobility of 
CTAP-III-des 1-15/NAP-2. 
Table 3. Synovial growth effects induced by CTAP-111 in binary 
with Other cYtokines 
Effect on growth measurements 
Combination* ’H-DNA ‘‘C-GAG 
Synergistic Synergistic 
antigen as a cleavage isoform suggests that the agonist Partly additive Partly additive 
Antagonistic Synergistic was recovered from the extravascular space and that it 
Additive Synergistic 
had been separated from the synovial circulation for Z;;::::: 1 tlF Antagonistic Synergistic 
an extended period of time prior to surgery. This c ~ ~ p - 1 1 1  + KE, Antagonistic Synergistic 
111 extracted from fresh platelets with acid-ethanol, 
from fresh platelet-releasate, and from platelet- 
Detection of a large proportion of the CTAP-I11 E:;;:::: 1 $E:F-BB Synergistic Additive 
c ~ ~ p - 1 1 1  + r~~~~ 
CTAP-111 + rIL-IP 
interpretation is based On Our experience that * CTAP-111 = connective tissue activating peptide-111; see Figures 
2-7 for other definitions. 
releasate thatis several days old (Figure 1) shows little 
or no evidence of proteolyic cleavage. It therefore 
seems likely that the CTAP-111 antigens demonstrated 
in Figure 1 did not originate from platelets that were 
merely trapped in vessels at the time of surgery, but 
derive instead from earlier platelet a-granule releasate 
from platelet thrombi in the microvasculature or in the 
extravascular matrix. 
The mobility of the cleavage isoform on SDS- 
PAGE is compatible with the presence of des 1-15/ 
NAP-2, but the far less common (and also biologically 
active) des 1-14 and 1-13 forms cannot be excluded 
until microsequencing has been accomplished (1 1,38). 
It is also pertinent to note that the presence of CTAP- 
I11 isoforms implies the delivery of at least 4 other 
platelet-derived growth factors to the synovial mem- 
brane, all with the potential for influencing inflamma- 
tion in that tissue. Findings of a recent study provided 
evidence that, in the rat, platelets mediate glomerular 
cell proliferation in immune complex nephritis induced 
by antimesangial cell antibodies (39), suggesting a 
central role for platelets in the inflammatory process. 
Cleavage of CTAP-111 to the des 1-ISNAP-2 
isoform not only may increase the anabolic activity of 
the agonist, it also confers neutrophil-activating and 
chemotactic activity to the agonist. Both native and 
chemically synthesized NAP-2 have been shown to 
induce cytosolic free calcium, elastase release, and 
chemotaxis in human neutrophils (40,41). Other data 
indicate that CTAP-I11 is not an attractant; chemotac- 
tic activity appears to result from amino terminal 
cleavage to the CTAP-111 des 1-13 and des 1-15NAP-2 
isoforms, which are able to interact with the NAP-I/ 
IL-8 receptor on human neutrophils (42). Other find- 
ings suggest that both CTAP-III-des I-15/NAP-2 and 
grolMGSA interact with two classes of receptors for 
NAP-l/IL-8 (43). The pathologic significance of these 
results is highlighted by recent data showing that intra- 
dermal injection of CTAP-III-des I-IYNAP-2 into rabbit 
skin promotes neutrophil accumulation and plasma leak- 
age when administered along with vasodilating sub- 
stances (44). 
Evidence supporting the presence of multiple 
cytokines in abnormal human synovium is persuasive; 
however, data are scarce concerning tissue cytokine 
concentrations or how these agonists act in the aggre- 
gate to influence synovial cell behavior. Since the net 
effects of a “cytokine network” may reflect the con- 
sequences of multiple cytokine4ellular interactions, 
we have attempted to enhance understanding of the 
behavior of synovial cells when they are confronted 
with more than one cytokine at a time. 
The measurements of growth-related activity of 
selected cytokines in binary combinations are summa- 
rized in Table 3. It is clear that synergistic interactions 
were more common when cytokine combinations were 
evaluated in the I4C-GAG assay; only the combina- 
tions of rPDGF-BB and rEGF with CTAP-I11 were 
synergistic in stimulating DNA synthesis. EGF is the 
best known member of a large family of cytokines that 
includes TGFa, platelet-derived EGF-like protein, and 
amphiregulin, all able to bind to EGF receptors and 
presumably to evoke characteristic EGF responses 
(45). Other widely distributed proteins with EGF-like 
domains, not yet known to bind to EGF receptors, 
include tissue-type plasminogen activator, clotting fac- 
tors IX and X, low density lipoprotein receptor, and 
proteoglycan core protein. 
The ability of PGE, and PGE2 to antagonize the 
action of CTAP-I11 on DNA synthesis was marked, 
but not complete. Others have shown that rIL-Ip and 
rTNFa in combination had a marked synergistic effect 
on both prostaglandin E and collagenase production, 
but only additive effects on GAG (hyaluronic acid) 
formation (46). PDGF-BB has also been shown to act 
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synergistically with IL- I a in promoting production of 
metalloproteinases in rabbit articular chondrocyte cul- 
tures (47). These  da ta  indicate that PDGF-BB and 
IL- 1 a each up-regulate cell receptors for the o ther  
agonist. The  possibility that this particular binary 
combination may exist in rheumatoid synovium is  
supported by immunologic evidence for  the presence 
of PDGF-B-like peptide in these tissues (48). 
The present results and earlier findings indicate 
that t he  difference between additive and  synergistic 
effects is influenced by the concentrations of t he  
agonists that are combined. The da ta  suggest that, in 
addition to endogenous factors, CTAP-I11 and other 
platelet-derived cytokines may have roles in the  regu- 
lation of synovial cell metabolism in RA and OA. I t  is 
likely that particular combinations of growth factors may 
be more important than single factors in the amplification 
or suppression of important cell functions. 
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